Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended June 30, 2025
Business Overview: BD is a global medical technology company operating through three segments: BD Medical, BD Life Sciences, and BD Interventional. The company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Key Financial Metrics
| Metric (Millions, except per share) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $5,509 | $4,990 | $15,949 | $14,741 |
| Operating Income | $882 | $602 | $1,882 | $1,775 |
| Net Income | $574 | $487 | $1,185 | $1,305 |
| Diluted EPS | $2.00 | $1.68 | $4.10 | $4.49 |
| Operating Cash Flow (9M) | $2,076 (2025) vs $2,666 (2024) | |||
| Total Debt | $19,341 (June 30, 2025) vs $20,110 (Sep 30, 2024) | |||
| Cash & Equivalents | $735 (June 30, 2025) vs $1,717 (Sep 30, 2024) | |||
| Gross Margin (Q3) | 47.8% (2025) vs 46.2% (2024) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenues increased 10.4% year-over-year. Growth was driven by the acquisition of Advanced Patient Monitoring (5.5% impact), volume growth (3.5%), and favorable foreign currency impacts (0.5%), partially offset by pricing (-0.5%).
- Segment Performance:
- Medical: Revenues up 14.4% to $2.927 billion, driven by Advanced Patient Monitoring and growth in Medication Management Solutions.
- Life Sciences: Revenues declined 0.5% to $1.254 billion due to lower sales in Diagnostic Solutions and Biosciences.
- Interventional: Revenues increased 7.2% to $1.328 billion, led by strong growth in Urology and Critical Care.
- Profitability: Operating income increased 46.5% in Q3 2025 compared to Q3 2024. Net income rose 17.9% to $574 million, despite higher interest expense and a higher effective tax rate (18.3% vs 2.6% in prior year).
- Acquisition Impact: The Q3 2025 results include the full quarter impact of the Advanced Patient Monitoring acquisition (completed Sept 2024), which contributed $278 million in revenue for the quarter.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Transaction: On July 13, 2025, BD entered a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. The transaction is structured as a Reverse Morris Trust, expected to close in Q1 2026. BD shareholders will own ~39.2% of the combined entity, and BD expects a cash distribution of approximately $4 billion.
- Regulatory Matters:
- FDA Warning Letter: BD received a Warning Letter in November 2024 regarding its Dispensing quality management system (Pyxis products). The company has accrued $114 million for estimated remediation costs as of June 30, 2025.
- Consent Decree: The Alaris infusion pump business operates under an FDA Consent Decree. No accruals are currently held for potential penalties, but the company faces potential fines of up to $15 million per year for violations.
- Legal Contingencies:
- Product Liability: Accruals for product liability claims (including hernia repair devices) totaled approximately $1.5 billion as of June 30, 2025.
- Ethylene Oxide Litigation: A jury awarded $20 million in compensatory damages in a Georgia case regarding EtO exposure; the punitive phase resulted in a mistrial. No judgment has been entered, and no amount has been accrued.
- Tariffs: Management estimates an impact of $90 million to fiscal year 2025 operating expenses due to tariffs on imported products/components.
- Share Repurchases: BD repurchased $750 million of common stock in the first nine months of fiscal 2025. As of June 30, 2025, 13 million shares remained available under authorized programs.
Investor Verification Checklist
- Waters Transaction Status: Monitor regulatory approvals and closing conditions for the Biosciences/Diagnostic Solutions combination with Waters, including the expected $4 billion cash distribution.
- FDA Remediation Costs: Verify if the accrued $114 million for the Dispensing Warning Letter is sufficient or if additional charges are required to address non-conformities.
- Product Liability Exposure: Review updates on the $1.5 billion product liability accrual, specifically regarding hernia repair device claims and the outcome of the Georgia EtO litigation.
- Advanced Patient Monitoring Integration: Assess the long-term margin contribution of the Advanced Patient Monitoring unit, noting the $336 million fair value step-up charge impacting 9M 2025 gross margin.
- Tariff Impact: Track the realization of the estimated $90 million tariff impact on operating expenses for the remainder of fiscal 2025.